LGALS1 and neoplasm: Galectin inhibitors are currently developed for clinical application [45, 46], and maybe extremely useful for both in- and ex vivo applications to boost the anti-tumor response, especially since these inhibitors can also abrogate the potential immunosuppressive effect of other galectins (e.g., galectin-1) secreted by tumor cells [47].